Last 12 months
Inside the activity.
0 purchase rows · 64 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 34 |
| Jan 2026 | 0 | 21 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 4 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 17, 2020 Filed Dec 18, 2020 23:26 UTC |
GIVEN DOUGLAS BDirector
|
SaleCommon Stock | 500 | $79.59 | $39,795.00 |
DisclosureSEC source: 0001209191-20-064497 · doc4.xml · nonDerivative · entry 5 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 15,000 F5 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.57 to $79.63, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · ownership.nature: Represents securities owned directly by Anne Given Trust ("AG Trust"). Mr. Given, as co-trustee of AG Trust, may be deemed to beneficially own the securities owned directly by AG Trust. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 23:26 UTC |
GIVEN DOUGLAS BDirector
|
SaleCommon Stock | 9,075 | $79.30 | $719,647.50 |
DisclosureSEC source: 0001209191-20-064497 · doc4.xml · nonDerivative · entry 4 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,738 F4 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.75 to $79.65, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| December 17, 2020 Filed Dec 29, 2020 22:55 UTC |
GIVEN DOUGLAS BDirector
|
GiftCommon Stock | 35 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065396 · doc4.xml · nonDerivative · entry 6 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,138 Read SEC document |
| December 17, 2020 Filed Dec 29, 2020 22:55 UTC |
GIVEN DOUGLAS BDirector
|
GiftCommon Stock | 35 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065396 · doc4.xml · nonDerivative · entry 5 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,173 Read SEC document |
| December 17, 2020 Filed Dec 29, 2020 22:55 UTC |
GIVEN DOUGLAS BDirector
|
GiftCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065396 · doc4.xml · nonDerivative · entry 4 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,208 Read SEC document |
| December 17, 2020 Filed Dec 29, 2020 22:55 UTC |
GIVEN DOUGLAS BDirector
|
GiftCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065396 · doc4.xml · nonDerivative · entry 3 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,408 Read SEC document |
| December 17, 2020 Filed Dec 29, 2020 22:55 UTC |
GIVEN DOUGLAS BDirector
|
GiftCommon Stock | 65 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065396 · doc4.xml · nonDerivative · entry 2 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,608 Read SEC document |
| December 17, 2020 Filed Dec 29, 2020 22:55 UTC |
GIVEN DOUGLAS BDirector
|
GiftCommon Stock | 65 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065396 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,673 Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 23:16 UTC |
Waddill William D.Director
|
SaleCommon Stock | 1,800 | $73.10 | $131,580.00 |
DisclosureSEC source: 0001209191-20-063035 · doc4.xml · nonDerivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 23:16 UTC |
Waddill William D.Director
|
SaleCommon Stock | 1,200 | $68.50 | $82,200.00 |
DisclosureSEC source: 0001209191-20-063035 · doc4.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,800 Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 00:07 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 38,676 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-20-062797 · doc4.xml · derivative · entry 9 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 840,543 Underlying: Common Stock · 38,676 shares Expires 2023-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 00:07 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
SaleCommon Stock | 4,003 | $71.61 | $286,654.83 |
DisclosureSEC source: 0001209191-20-062797 · doc4.xml · nonDerivative · entry 7 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,505,237 F5 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.33 to $72.13, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F6 · balance_after: Includes a total of 900,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 00:07 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
SaleCommon Stock | 5,880 | $70.87 | $416,715.60 |
DisclosureSEC source: 0001209191-20-062797 · doc4.xml · nonDerivative · entry 6 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,509,240 F4 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.32 to $71.30, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 00:07 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
SaleCommon Stock | 12,067 | $69.80 | $842,276.60 |
DisclosureSEC source: 0001209191-20-062797 · doc4.xml · nonDerivative · entry 5 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,515,120 F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.27 to $70.25, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 00:07 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
SaleCommon Stock | 16,726 | $67.27 | $1,125,158.02 |
DisclosureSEC source: 0001209191-20-062797 · doc4.xml · nonDerivative · entry 4 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,527,187 F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.26 to $69.26, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 00:07 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 38,676 | $2.01 | $77,738.76 |
DisclosureSEC source: 0001209191-20-062797 · doc4.xml · nonDerivative · entry 3 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,543,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2020 Filed Dec 11, 2020 00:07 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 16,324 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-20-062797 · doc4.xml · derivative · entry 8 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 879,219 Underlying: Common Stock · 16,324 shares Expires 2023-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| December 08, 2020 Filed Dec 11, 2020 00:07 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
SaleCommon Stock | 16,324 | $67.97 | $1,109,542.28 |
DisclosureSEC source: 0001209191-20-062797 · doc4.xml · nonDerivative · entry 2 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,505,237 F1 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.50 to $68.29, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| December 08, 2020 Filed Dec 11, 2020 00:07 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 16,324 | $2.01 | $32,811.24 |
DisclosureSEC source: 0001209191-20-062797 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,521,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2020 Filed Dec 18, 2020 23:26 UTC |
GIVEN DOUGLAS BDirector
|
GiftCommon Stock | 15,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064497 · doc4.xml · nonDerivative · entry 3 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 15,500 F3 · ownership.nature: Represents securities owned directly by Katherine Given Ligtenberg Trust ("KGL Trust"). Mr. Given, as co-trustee of KGL Trust, may be deemed to beneficially own the securities owned directly by KGL Trust. Read SEC document |
| December 07, 2020 Filed Dec 18, 2020 23:26 UTC |
GIVEN DOUGLAS BDirector
|
GiftCommon Stock | 15,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064497 · doc4.xml · nonDerivative · entry 2 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 15,500 F2 · ownership.nature: Represents securities owned directly by Anne Given Trust ("AG Trust"). Mr. Given, as co-trustee of AG Trust, may be deemed to beneficially own the securities owned directly by AG Trust. Read SEC document |
| December 07, 2020 Filed Dec 18, 2020 23:26 UTC |
GIVEN DOUGLAS BDirector
|
GiftCommon Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064497 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,813 F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| December 04, 2020 Filed Jan 8, 2022 01:16 UTC |
O'Brien PatrickGeneral Counsel
|
GiftCommon Stock | 800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002599 · doc4.xml · nonDerivative · entry 6 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,075 Read SEC document |
| November 20, 2020 Filed Nov 23, 2020 22:58 UTC |
Bradshaw CurtChief Scientific Officer
|
SaleCommon Stock | 15,625 | $68.73 | $1,073,906.25 |
DisclosureSEC source: 0001209191-20-060047 · doc4.xml · nonDerivative · entry 2 Bradshaw Curt · CIK 0001794633 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.16 to $69.06, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: 93,750 restricted stock units previously reported have been removed from this amount of securities beneficially owned due to forfeiture. Read SEC document |
| November 19, 2020 Filed Nov 20, 2020 23:03 UTC |
San Martin JavierChief Medical Officer
|
SaleCommon Stock | 19,500 | $69.39 | $1,353,105.00 |
DisclosureSEC source: 0001209191-20-059753 · doc4.xml · nonDerivative · entry 1 San Martin Javier · CIK 0001794629 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,500 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 22:58 UTC |
Bradshaw CurtChief Scientific Officer
|
SaleCommon Stock | 15,625 | $69.39 | $1,084,218.75 |
DisclosureSEC source: 0001209191-20-060047 · doc4.xml · nonDerivative · entry 1 Bradshaw Curt · CIK 0001794633 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 22:49 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 43,505 | $0.00 Strike: $14.54 | $0.00 |
DisclosureSEC source: 0001209191-20-058075 · doc4.xml · derivative · entry 4 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,505 shares Expires 2024-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents the first vesting date. Option vested over four years from date of grant. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 22:49 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
SaleCommon Stock | 17,665 | $69.86 | $1,234,076.90 |
DisclosureSEC source: 0001209191-20-058075 · doc4.xml · nonDerivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,668 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.51 to $70.06, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 22:49 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
SaleCommon Stock | 25,840 | $69.04 | $1,783,993.60 |
DisclosureSEC source: 0001209191-20-058075 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,333 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.51 to $69.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 22:49 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
Exercise / conversionCommon Stock | 43,505 | $14.54 | $632,562.70 |
DisclosureSEC source: 0001209191-20-058075 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 471,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 23, 2020 Filed Oct 23, 2020 23:35 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
SaleCommon Stock | 12,272 | $58.57 | $718,771.04 |
DisclosureSEC source: 0001209191-20-055732 · doc4.xml · nonDerivative · entry 2 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,505,237 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F4 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.52 to $58.60, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes a total of 900,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| October 23, 2020 Filed Oct 23, 2020 23:35 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
SaleCommon Stock | 87,728 | $58.16 | $5,102,260.48 |
DisclosureSEC source: 0001209191-20-055732 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,517,509 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.51 to $58.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes a total of 900,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 22:02 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 29,166 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001209191-20-055599 · doc4.xml · derivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,505 Underlying: Common Stock · 29,166 shares Expires 2026-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents the first vesting date. Option vested over four years from date of grant. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 22:02 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
SaleCommon Stock | 29,166 | $54.04 | $1,576,130.64 |
DisclosureSEC source: 0001209191-20-055599 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,668 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.00 to $54.07, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 22:02 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
Exercise / conversionCommon Stock | 29,166 | $6.15 | $179,370.90 |
DisclosureSEC source: 0001209191-20-055599 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 09, 2020 Filed Oct 13, 2020 22:01 UTC |
Ferrari MauroDirector
|
SaleCommon Stock | 10,000 | $48.00 | $480,000.00 |
DisclosureSEC source: 0001209191-20-054714 · doc4.xml · nonDerivative · entry 1 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,971 Read SEC document |
| October 08, 2020 Filed Oct 26, 2020 22:02 UTC |
De Backer MarianneDirector
|
PurchaseCommon Stock | 500 | $50.00 | $25,000.00 |
DisclosureSEC source: 0001209191-20-055851 · doc4.xml · nonDerivative · entry 2 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Read SEC document |
| October 08, 2020 Filed Oct 26, 2020 22:02 UTC |
De Backer MarianneDirector
|
PurchaseCommon Stock | 500 | $50.93 | $25,465.00 |
DisclosureSEC source: 0001209191-20-055851 · doc4.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 22:08 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $9.90 | $0.00 |
DisclosureSEC source: 0001209191-20-046846 · doc4.xml · derivative · entry 3 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 895,543 Underlying: Common Stock · 50,000 shares Expires 2020-08-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 22:08 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
SaleCommon Stock | 50,000 | $41.35 | $2,067,500.00 |
DisclosureSEC source: 0001209191-20-046846 · doc4.xml · nonDerivative · entry 2 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,605,237 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This option exercise was completed as the underlying option was due to expire in August 2020. F2 · balance_after: Includes a total of 1,100,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 22:08 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 50,000 | $9.90 | $495,000.00 |
DisclosureSEC source: 0001209191-20-046846 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,655,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 22:02 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
SaleCommon Stock | 23 | $39.55 | $909.65 |
DisclosureSEC source: 0001209191-20-039148 · doc4.xml · nonDerivative · entry 2 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,605,237 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 22:02 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
SaleCommon Stock | 99,977 | $38.81 | $3,880,107.37 |
DisclosureSEC source: 0001209191-20-039148 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,605,260 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.46 to $39.45, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| June 15, 2020 Filed Jun 24, 2020 22:10 UTC |
De Backer MarianneDirector
|
PurchaseCommon Stock | 500 | $31.33 | $15,665.00 |
DisclosureSEC source: 0001209191-20-038767 · doc4.xml · nonDerivative · entry 8 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC |
PERRY MICHAEL SDirector
|
Exercise / conversionCommon Stock (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · derivative · entry 12 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2021-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC |
PERRY MICHAEL SDirector
|
Exercise / conversionCommon Stock (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · derivative · entry 11 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 15,000 shares Expires 2022-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Option vested entirely on the one year anniversary of the grant date. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC |
PERRY MICHAEL SDirector
|
Exercise / conversionCommon Stock (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · derivative · entry 10 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 10,000 shares Expires 2022-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Option vested entirely on the one year anniversary of the grant date. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC |
PERRY MICHAEL SDirector
|
Exercise / conversionCommon Stock (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · derivative · entry 9 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 15,000 shares Expires 2023-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Option vested entirely on the one year anniversary of the grant date. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC |
PERRY MICHAEL SDirector
|
Exercise / conversionCommon Stock (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · derivative · entry 8 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 5,000 shares Expires 2023-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Option vested entirely on the one year anniversary of the grant date. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC |
PERRY MICHAEL SDirector
|
Exercise / conversionCommon Stock (right to buy) · Derivative | 7,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · derivative · entry 7 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 7,000 shares Expires 2023-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Option vested entirely on the one year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.